Found 5 matching trials
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
PHASE3This study will determine whether participants who receive the vaccine V419...
Location
Multiple Locations
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
PHASE3To evaluate the immune response and the safety of a primary series schedule...
Location
Multiple Locations
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
PHASE3The primary objectives of this study are to evaluate the immunogenicity and...
Location
Multiple Locations
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®
PHASE2PR5I, a hexavalent pediatric combination vaccine is being developed to redu...
Location
Multiple Locations
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
PHASE3This study will determine whether participants who receive V419 (PR5I) at 2...
Location
Multiple Locations